Lindsey Rolfe - Jun 1, 2021 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
Officer
Signature
/s/ Lindsey Rolfe
Stock symbol
CLVS
Transactions as of
Jun 1, 2021
Transactions value $
-$1,813
Form type
4
Date filed
6/3/2021, 07:00 PM
Next filing
Jun 11, 2021
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 +687 +49.93% $0.00 2.06K Jun 1, 2021 Common Stock 687 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance